Atlas Trials

Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS

Clinical trial NCT04874597 · UNKNOWN

Trial details

NCT number
NCT04874597
Sponsor
Dr Recai Turkoglu
Status
UNKNOWN
Study type
OBSERVATIONAL
Multiple Sclerosis
Start date
2021-11-15
Primary completion
2025-04-10
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.